AIM: As a consequence of the improved survival of patients and of cost-effectiveness requirements for new treatments, health-related quality of life (HRQoL) issues have gained increasing attention in colorectal cancer (CRC). This cross-sectional study assesses HRQoL in several health states of CRC and explores factors influencing HRQoL. METHOD: Five hundred and eight Finnish CRC patients (aged 26-96 years; colon cancer 56%; women 47%) assessed their HRQoL using generic 15D and EQ-5D and cancer-specific EORTC QLQ-C30 questionnaires. Patients were divided into five groups: primary treatment, rehabilitation, remission, metastatic disease and palliative care. The patients' HRQoL was compared with population reference values. Multivariate modelling was used to find factors associated with HRQoL scores. RESULTS: The HRQoL of CRC patients is fairly good and comparable with that of the standardized general population except for those under palliative care. The mean 15D score of patients in the primary treatment group was 0.889 (95% CI 0.869-0.914), in rehabilitation 0.877 (0.855-0.907), in remission 0.886 (0.875-0.903), in metastatic disease 0.860 (0.844-0.878) and in palliative care 0.758 (0.716-0.808). The respective EQ-5D scores were 0.760 (0.699-0.823), 0.835 (0.777-0.881), 0.850 (0.828-0.882), 0.820 (0.783-0.858) and 0.643 (0.546-0.747). Multivariate analysis showed that fatigue, pain, age and financial difficulties had a marked negative impact on HRQoL. CONCLUSION: The mean HRQoL scores of CRC patients varied considerably depending on the HRQoL instrument used, but remained surprisingly good up to the palliative stage. In addition to age- and cancer-related symptoms, financial difficulties also had a clear negative impact on HRQoL, which needs to be taken into consideration when supporting patient HRQoL. Colorectal Disease
AIM: As a consequence of the improved survival of patients and of cost-effectiveness requirements for new treatments, health-related quality of life (HRQoL) issues have gained increasing attention in colorectal cancer (CRC). This cross-sectional study assesses HRQoL in several health states of CRC and explores factors influencing HRQoL. METHOD: Five hundred and eight Finnish CRC patients (aged 26-96 years; colon cancer 56%; women 47%) assessed their HRQoL using generic 15D and EQ-5D and cancer-specific EORTC QLQ-C30 questionnaires. Patients were divided into five groups: primary treatment, rehabilitation, remission, metastatic disease and palliative care. The patients' HRQoL was compared with population reference values. Multivariate modelling was used to find factors associated with HRQoL scores. RESULTS: The HRQoL of CRC patients is fairly good and comparable with that of the standardized general population except for those under palliative care. The mean 15D score of patients in the primary treatment group was 0.889 (95% CI 0.869-0.914), in rehabilitation 0.877 (0.855-0.907), in remission 0.886 (0.875-0.903), in metastatic disease 0.860 (0.844-0.878) and in palliative care 0.758 (0.716-0.808). The respective EQ-5D scores were 0.760 (0.699-0.823), 0.835 (0.777-0.881), 0.850 (0.828-0.882), 0.820 (0.783-0.858) and 0.643 (0.546-0.747). Multivariate analysis showed that fatigue, pain, age and financial difficulties had a marked negative impact on HRQoL. CONCLUSION: The mean HRQoL scores of CRC patients varied considerably depending on the HRQoL instrument used, but remained surprisingly good up to the palliative stage. In addition to age- and cancer-related symptoms, financial difficulties also had a clear negative impact on HRQoL, which needs to be taken into consideration when supporting patient HRQoL. Colorectal Disease
Authors: K Aro; L Bäck; V Loimu; K Saarilahti; S Rogers; H Sintonen; R Roine; Antti Mäkitie Journal: Eur Arch Otorhinolaryngol Date: 2015-07-28 Impact factor: 2.503
Authors: Catherine E Mosher; Joseph G Winger; Barbara A Given; Paul R Helft; Bert H O'Neil Journal: Psychooncology Date: 2015-08-27 Impact factor: 3.894
Authors: Niilo Färkkilä; Saku Torvinen; Risto P Roine; Harri Sintonen; Juha Hänninen; Kimmo Taari; Tiina Saarto Journal: Qual Life Res Date: 2013-11-01 Impact factor: 4.147
Authors: Christopher S Lathan; Angel Cronin; Reginald Tucker-Seeley; S Yousuf Zafar; John Z Ayanian; Deborah Schrag Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544
Authors: David D Kim; Parke E Wilde; Dominique S Michaud; Junxiu Liu; Lauren Lizewski; Jennifer Onopa; Dariush Mozaffarian; Fang Fang Zhang; John B Wong Journal: Am J Prev Med Date: 2019-09-26 Impact factor: 5.043
Authors: V Loimu; A A Mäkitie; L J Bäck; H Sintonen; P Räsänen; R Roine; K Saarilahti Journal: Eur Arch Otorhinolaryngol Date: 2014-07-02 Impact factor: 2.503
Authors: Dirk Mehrens; Marcus Unterrainer; Stefanie Corradini; Maximilian Niyazi; Farkhad Manapov; C Benedikt Westphalen; Matthias F Froelich; Moritz Wildgruber; Max Seidensticker; Jens Ricke; Johannes Rübenthaler; Wolfgang G Kunz Journal: Front Oncol Date: 2021-06-15 Impact factor: 6.244